Eligibility for omecamtiv mecarbil in a real-world heart failure population: Data from the Swedish Heart Failure Registry.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Heart Failure*/drug therapy ; Heart Failure*/physiopathology ; Heart Failure*/epidemiology ; Registries* ; Stroke Volume*/drug effects; Humans ; Sweden/epidemiology ; Male ; Female ; Aged ; Middle Aged ; Natriuretic Peptide, Brain/blood ; Peptide Fragments/blood ; Urea/analogs & derivatives ; Urea/blood ; Urea/therapeutic use ; Eligibility Determination ; Patient Selection ; Aged, 80 and over

Aims: We assessed eligibility for omecamtiv mecarbil (OM) in a real-world cohort with heart failure with reduced ejection fraction (HFrEF) according to the selection criteria of the GALACTIC-HF trial (trial scenario) and selected trial´s criteria more likely to impact real-world use (pragmatic scenario).
Methods and Results: We included 31,015 patients with HFrEF lasting ≥3 months and registered in the Swedish HF registry between 2000-2021. Trial eligibility was calculated by applying all the GALACTIC-HF selection criteria. The pragmatic scenario considered only the New York Heart Association class, history of worsening HF, N-terminal pro-B-type natriuretic peptides (NT-proBNP), blood pressure and renal failure criteria defined as in the trial. Eligibility for OM in chronic HFrEF was 21% and 36% in the trial and pragmatic scenarios, respectively. Eligibility was higher in those with EF<30% (trial: 27%, pragmatic: 44%), in-patients (trial:30%, pragmatic:57%), severe HF (trial: 35%, pragmatic: 60%), NYHA class III-IV (trial: 26%, pragmatic: 45%), and NT-proBNP≥5,000pg/mL (trial: 30%, pragmatic: 51%). The criteria that most limited eligibility were history of a recent worsening HF event (60% eligible in chronic HFrEF), elevated NT-proBNP (82% eligible), and deviating blood pressure (82% eligible). Overall, eligible patients were characterized by more severe HF and higher CV event-rates in both scenarios, and higher comorbidity burden in the pragmatic scenario.
Conclusion: Approximately 21% of real-world chronic HFrEF patients would be eligible for OM according to the GALACTIC-HF selection criteria, and 36% according to the criteria more likely to affect OM use in clinical practice. Criteria in both scenarios identified a patient-group with severe HF and high CV event-rates.
Competing Interests: FL has no conflicts of interest to declare. NØ has no conflicts of interest to declare. MM reports grants and other from Amgen, Abbott Vascular, Edwards Therapeutics, Servier, WindTree Therapeutics, Actelion, Livanova, Vifor Pharma. GR reports no conflicts of interest. UD reports research grants from AstraZeneca, Boehringer Ingelheim, Pfizer, Vifor, Boston Scientific, Roche Diagnostics and honoraria/consultancies from Amgen, Pfizer and AstraZeneca all outside the present manuscript. PM has no conflicts of interest to declare. CH none related to the present work; unrelated to the present work: consulting fees from Novartis, Roche Diagnostics, and AnaCardio; speaker fees from Novartis and Merck Sharp & Dohme. LHL none related to the present work; unrelated to the present work: grants, consulting, honoraria: Abbot, Alleviant, AstraZeneca, Bayer, Biopeutics, Boehringer Ingelheim, Edwards, FineHeart, MedScape/WebMD, Merck/MSD, Novartis, Novo Nordisk, OrionPharma, Pharmacosmos, Radcliffe Cardiology, Roche, Sanofi, Servier, Translational Medicines Academy, Vifor; Stock ownership: AnaCardio. GS received financial support from Cytokinetics for performing this investigator-initiated study. GS reports grants and personal fees from Vifor, personal fees and grants from Boehringer Ingelheim, grants and personal fees from AstraZeneca, personal fees from Roche, grants and personal fees from Servier, grants and personal fees from Novartis, grants and personal fees from Cytokinetics, personal fees from Medtronic, grants from Boston Scientific, grants and personal fees from Pharmacosmos, grants from Merck, grants from Bayer, personal fees from INTAS, personal fees from Abbott, outside the submitted work. This does not alter our adherence to PLOS ONE policies on sharing data and materials
(Copyright: © 2024 Lindberg et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

Clin Res Cardiol. 2023 Aug;112(8):1067-1076. (PMID: 36800016)
J Am Coll Cardiol. 2019 May 14;73(18):2345-2353. (PMID: 31072579)
Nat Rev Cardiol. 2015 Apr;12(4):220-9. (PMID: 25666406)
Circ Heart Fail. 2017 Sep;10(9):. (PMID: 28903983)
JAMA Cardiol. 2022 Jan 1;7(1):26-34. (PMID: 34643642)
J Intern Med. 2021 Mar;289(3):369-384. (PMID: 32776357)
Eur Heart J. 2022 Jun 14;43(23):2212-2220. (PMID: 35325102)
Eur Heart J. 2019 Nov 21;40(44):3626-3644. (PMID: 30295807)
Card Fail Rev. 2017 Apr;3(1):7-11. (PMID: 28785469)
Clin Pharmacokinet. 2021 Aug;60(8):1041-1048. (PMID: 33768487)
Eur J Heart Fail. 2023 Aug;25(8):1418-1428. (PMID: 37323078)
J Am Heart Assoc. 2022 Apr 5;11(7):e023766. (PMID: 35322672)
Eur J Heart Fail. 2022 Jun;24(6):1047-1062. (PMID: 35278267)
Eur Heart J Qual Care Clin Outcomes. 2022 Oct 26;8(7):761-769. (PMID: 34596659)
Cureus. 2021 Jan 1;13(1):e12419. (PMID: 33542867)
N Engl J Med. 2021 Jan 14;384(2):105-116. (PMID: 33185990)
Eur J Heart Fail. 2018 Sep;20(9):1326-1334. (PMID: 29578280)
Eur Heart J. 2022 Dec 21;43(48):5006-5016. (PMID: 35675469)
Eur J Heart Fail. 2023 Apr;25(4):457-468. (PMID: 36847113)
Eur J Heart Fail. 2017 Sep;19(9):1107-1116. (PMID: 28229520)
Eur J Heart Fail. 2020 Nov;22(11):2160-2171. (PMID: 32985088)
Eur J Heart Fail. 2021 Nov;23(11):1942-1951. (PMID: 34145680)
Eur J Heart Fail. 2018 Nov;20(11):1505-1535. (PMID: 29806100)
Heart Fail Rev. 2022 May;27(3):741-753. (PMID: 33471236)
Drugs. 2011 Mar 26;71(5):515-25. (PMID: 21443277)
J Card Fail. 2022 Jul;28(7):1050-1062. (PMID: 35550428)
Eur Heart J Cardiovasc Pharmacother. 2023 Jun 2;9(4):343-352. (PMID: 36718512)
JACC Heart Fail. 2023 May;11(5):596-606. (PMID: 36732099)
J Am Coll Cardiol. 2021 Jul 13;78(2):97-108. (PMID: 34015475)
ESC Heart Fail. 2022 Jun;9(3):1507-1523. (PMID: 35352499)
Ups J Med Sci. 2019 Jan;124(1):65-69. (PMID: 30092697)

2M19539ERK (omecamtiv mecarbil)
114471-18-0 (Natriuretic Peptide, Brain)
0 (pro-brain natriuretic peptide (1-76))
0 (Peptide Fragments)
8W8T17847W (Urea)

Date Created: 20240524 Date Completed: 20240524 Latest Revision: 20240526

20240526

PMC11125482

10.1371/journal.pone.0303348

38787867